Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 4Unknown 2Completed 2Terminated 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6Gynecologic 6Breast 6Gastrointestinal 4CNS 3Tumor-Agnostic 2Lymphoid 2Head & Neck 2Dermatologic 2Sarcoma 1Other solid neoplasm 1Other neoplasm 1Other hematologic neoplasm 1Genitourinary 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Adenocarcinoma, Follicular 1

Interventions

Everolimus 10lanreotide 4Capecitabine 4pasireotide 3lutetium Lu 177 dotatate 3lenvatinib 3fosbretabulin 3Temozolomide 3Sorafenib 3Paclitaxel 3Octreotide 3Nivolumab 3Magnetic Resonance Spectroscopy 3Filgrastim 3Erlotinib Hydrochloride 3Doxorubicin 3trifluridine tipiracil drug combination 2surufatinib 2pembrolizumab 2pegfilgrastim 2gallium Ga 68 dotatate 2durvalumab 2dactolisib 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Sunitinib 2Rosiglitazone 2Radiotherapy 2Panobinostat 2Mitotane 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Fluorodeoxyglucose F18 × Endocrine × Clear all
NCT00095693 2014-01-16

Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
25 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡